Ampligen has not been approved by the FDA or marketed in the US. & We continue to pursue our Ampligen NDA, for the treatment of CFS with the FDA. & The product will be marketed by GP Pharm, our commercial partner in Latin America. Up to 24 patients to be enrolled. Protocol design and funding currently being finalized. & & & & People with ME/CFS are often not able to do their usual activities. This symptom is known as post-exertional malaise (PEM). There have been delays related to importing Ampligen to China. We will announce when the shipment for testing purposes has been completed. It is planned that the phase 1/2a study will enroll up to 44 patients in two stages. We reported in September 2020 that recruitment in the trial had begun. We are currently exploring an expansion of this relationship. & Such events could materially and adversely impact our operations. In addition, we have no basis for estimating when material net cash inflows may commence. The contracts augment our existing fill and finish capacity. The average daily trading volume of our common stock varies significantly. & ldquo;Business”, Part I; Item 3. & We have filed provisional patent applications related to the COVID-19 coronavirus.